A Phase III Clinical Trial Evaluating the Efficacy and Safety of TriThien Duoc Capsules in Grade II Internal Haemorrhoids Patients With Bleeding Compared to Diosmin.

\- Inclusion Criteria Patients must meet all of the following criteria to be eligible for the study: * Age 18 to 65 years * Diagnosis of grade II internal hemorrhoids with bleeding, presenting with the following symptoms: Hemorrhoids prolapse with gentle straining and retract spontaneously Presence of blood in stool Congested and/or bleeding hemorrhoids * Having symptoms such as anal pain and anal itching * Willingness to voluntarily participate in the study - Exclusion Criteria Patients meeting any of the following criteria will be excluded from the study: * History of malignancy, including colon cancer and other cancers * Anal polyps and proctitis * Anal fissures with bleeding * Systemic diseases, such as hypertension, liver failure, kidney failure, heart failure, and coagulation disorders. * Other severe acute or chronic illnesses * Mixed hemorrhoids or conditions requiring immediate surgical intervention, such as hematoma, severe bleeding, or hemorrhoidal infarction * Recent use of other hemorrhoid medications (within 7 days prior to study enrollment) * Known allergy to any component of the study medications * Pregnant or lactating women * Patients will be withdrawn from the study if they: Do not adhere to the treatment regimen, including missing medication for more than 3 consecutive days. Or Use other prohibited medications during the study period. Or require routine medical care at the hospital due to non-compliance or other medical reasons.